MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR.

Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Surmodics shareholders will receive only $43.00 per share in cash, for a total equity valuation of approximately $627 million. The transaction agreement unreasonably limits competing transactions for Surmodics by imposing a significant penalty if Surmodics accepts a competing bid. Surmodics insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Surmodics' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Surmodics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP